Prevalence of Medication Nonadherence to Co-medication Compared to Immunosuppressants in Heart Transplant Recipients: Findings From the International Cross-sectional BRIGHT Study
R. Helmy
,
K. Denhaerynck
,
L. Berben
,
F. Dobbels
,
C. L. Russell
,
B. D. Roza
,
S. de Geest
,
M. G. Crespo-Leiro
,
S. Guppies
,
P. de Simone
,
A. Groenewoud
,
C. Kugler
,
L. Ohler
,
J. van Cleemput
,
A. J. Poncelet
,
L. Sebbag
(1)
,
M. Michel
,
A. Bernard
(2)
,
A. Doesch
,
U. Livi
,
L. Potena
,
V. Brossa-Loidi
,
J. Segovia-Cubero
,
L. Almenar-Bonet
,
C. S. Saint-Gerons
,
P. Mohacsi
,
E. Horvath
(3)
,
C. Riotto
,
G. Parry
,
A. Firouzi
,
S. Kozuszko
,
H. Haddad
(4)
,
A. Kaan
,
G. Fisher
,
T. Miller
,
M. Flattery
,
K. Ludrosky
,
N. Albert
,
B. Coleman
,
J. Trammell
,
F. Epstein
,
K. St Clair
,
A. Kao
,
M. Molina
,
K. R. Canales
,
S. S. De Almeida
,
A. C. Ayoub
,
F. Barone
(5)
,
M. Harkess
,
J. Maddicks-Law
,
Bright Study Team
1
Pôle Médico-Chirurgical de Transplantation Cardiaque Adulte
2 LabEx LipSTIC - Laboratoire d'Excellence : Lipoprotéines et Santé : prévention et Traitement des maladies Inflammatoires et du Cancer
3 EPFL - Ecole Polytechnique Fédérale de Lausanne
4 LIA - Laboratoire Informatique d'Avignon
5 ESPCI Paris - Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris
2 LabEx LipSTIC - Laboratoire d'Excellence : Lipoprotéines et Santé : prévention et Traitement des maladies Inflammatoires et du Cancer
3 EPFL - Ecole Polytechnique Fédérale de Lausanne
4 LIA - Laboratoire Informatique d'Avignon
5 ESPCI Paris - Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris
R. Helmy
- Function : Author
K. Denhaerynck
- Function : Author
L. Berben
- Function : Author
F. Dobbels
- Function : Author
C. L. Russell
- Function : Author
B. D. Roza
- Function : Author
S. de Geest
- Function : Author
M. G. Crespo-Leiro
- Function : Author
S. Guppies
- Function : Author
P. de Simone
- Function : Author
A. Groenewoud
- Function : Author
C. Kugler
- Function : Author
L. Ohler
- Function : Author
J. van Cleemput
- Function : Author
A. J. Poncelet
- Function : Author
M. Michel
- Function : Author
A. Doesch
- Function : Author
U. Livi
- Function : Author
L. Potena
- Function : Author
V. Brossa-Loidi
- Function : Author
J. Segovia-Cubero
- Function : Author
L. Almenar-Bonet
- Function : Author
C. S. Saint-Gerons
- Function : Author
P. Mohacsi
- Function : Author
C. Riotto
- Function : Author
G. Parry
- Function : Author
A. Firouzi
- Function : Author
S. Kozuszko
- Function : Author
A. Kaan
- Function : Author
G. Fisher
- Function : Author
T. Miller
- Function : Author
M. Flattery
- Function : Author
K. Ludrosky
- Function : Author
N. Albert
- Function : Author
B. Coleman
- Function : Author
J. Trammell
- Function : Author
F. Epstein
- Function : Author
K. St Clair
- Function : Author
A. Kao
- Function : Author
M. Molina
- Function : Author
K. R. Canales
- Function : Author
S. S. De Almeida
- Function : Author
A. C. Ayoub
- Function : Author
M. Harkess
- Function : Author
J. Maddicks-Law
- Function : Author
Bright Study Team
- Function : Author
Abstract
Purpose: To assess and compare the prevalence of medication nonadherence (MNA) (implementation and persistence) to immunosuppressants and co-medications in heart transplant recipients. Methods: MNA prevalence was assessed using the Basel Assessment of Adherence to Immunosuppressive Medications Scale (self-report) and compared using logistic regression in a 4-continent sample of 1397 heart transplant recipients from 36 heart transplant centers in 11 countries. Findings: MNA was significantly (alpha = 0.05) higher to co-medications than to immunosuppressants (taking nonadherence: 23.9% vs 17.3%; odds ratio [OR] = 1.5; 95% CI, 1.30-1.73; drug holiday: 5.7% vs 1.9%; OR = 3.17; 95% CI, 2.13-4.73; dose alteration: 3.8% vs 1.6%; OR = 2.46; 95% CI, 1.49-4.06; and discontinuation: 2.6% vs 0.5%; OR = 5.15; 95% CI, 2.36-11.20). (C) 2018 Elsevier Inc. All rights reserved.